{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:31:04Z","timestamp":1793647864271,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01029-y","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:18:40Z","timestamp":1774984720000},"page":"1091-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b\/3 and ALLEGRO-LT Phase 3 Clinical Studies"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04006457","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04517864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02974868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Maryanne","family":"Senna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Kinoshita-Ise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"2","key":"1029_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PSC, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.10.014.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1029_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.032.","journal-title":"J Am Acad Dermatol"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366. https:\/\/doi.org\/10.2147\/CCID.S245649.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1029_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"MA Richard","year":"2018","unstructured":"Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the OBJECTIFS PEAU study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371. https:\/\/doi.org\/10.1111\/jdv.14959.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1029_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365. https:\/\/doi.org\/10.1111\/bjd.20628.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1029_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556-558.e1. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.048.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1029_CR7","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King BA, Mirmirani P, et al. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138. https:\/\/doi.org\/10.1016\/j.jisp.2020.05.007.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"6","key":"1029_CR8","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s13555-025-01417-y","volume":"15","author":"KA Hanson","year":"2025","unstructured":"Hanson KA, Va\u00f1\u00f3-Galv\u00e1n S, Messenger A, et al. Comparison of Dermatology Life Quality Index scores in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb). 2025;15(6):1543\u201353. https:\/\/doi.org\/10.1007\/s13555-025-01417-y.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"9","key":"1029_CR9","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1007\/s12325-025-03302-8","volume":"42","author":"KA Hanson","year":"2025","unstructured":"Hanson KA, Austin J, Clayton N, et al. Patient-reported psychosocial burdens and quality of life and work productivity impacts among patients with clinically distinct alopecia areata severity profiles. Adv Ther. 2025;42(9):4556\u201370. https:\/\/doi.org\/10.1007\/s12325-025-03302-8.","journal-title":"Adv Ther"},{"issue":"12","key":"1029_CR10","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s13555-024-01280-3","volume":"14","author":"P Anderson","year":"2024","unstructured":"Anderson P, Piercy J, Austin J,\u00a0et al. Alopecia areata treatment patterns and satisfaction: results of a real-world cross-sectional survey in Europe. Dermatol Ther (Heidelb). 2024;14(12):3243\u201358. https:\/\/doi.org\/10.1007\/s13555-024-01280-3.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1029_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. https:\/\/doi.org\/10.1038\/nrdp.2017.11.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1029_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VWY, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370. https:\/\/doi.org\/10.1111\/ajd.12941.","journal-title":"Australas J Dermatol"},{"issue":"18","key":"1029_CR13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"1029_CR14","unstructured":"Sun Pharmaceutical Industries Ltd. U.S. FDA approves LEQSELVI\u2122 (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata. Published 2024. https:\/\/sunpharma.com\/wp-content\/uploads\/2024\/07\/Sunpharma-LEQSELVI-Approval-Scenario-Press-Release.pdf. Accessed Aug 2024."},{"issue":"10387","key":"1029_CR15","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Gubelin Harcha W, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"issue":"6","key":"1029_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jdv.20547","volume":"39","author":"B King","year":"2025","unstructured":"King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163\u201373. https:\/\/doi.org\/10.1111\/jdv.20547.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1029_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljae365.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1029_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314. https:\/\/doi.org\/10.1007\/s40257-024-00846-3.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1029_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad253.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1029_CR20","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/jdv.20698","volume":"40","author":"Z Reguiai","year":"2025","unstructured":"Reguiai Z, Asfour L, Staumont-Sall\u00e9 D, et al. SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata. J Eur Acad Dermatol Venereol. 2025;40(1):e5\u20137. https:\/\/doi.org\/10.1111\/jdv.20698.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1029_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139. https:\/\/doi.org\/10.1111\/bjd.18883.","journal-title":"Br J Dermatol"},{"key":"1029_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1695618","volume":"12","author":"Y Wenjie","year":"2025","unstructured":"Wenjie Y, Yue W, Mengjiao W, et al. Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study. Front Med. 2025;12:1695618. https:\/\/doi.org\/10.3389\/fmed.2025.1695618.","journal-title":"Front Med"},{"issue":"1","key":"1029_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1029_CR24","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s13555-023-01033-8","volume":"13","author":"S Taylor","year":"2023","unstructured":"Taylor S, Korman NJ, Tsai T-F, et al. Efficacy of baricitinib in patients with various degrees of alopecia areata severity: post hoc analysis from BRAVE-AA1 and BRAVE-AA2. Dermatol Ther (Heidelb). 2023;13(12):3181\u201391. https:\/\/doi.org\/10.1007\/s13555-023-01033-8.","journal-title":"Dermatol Ther (Heidelb)"}],"updated-by":[{"DOI":"10.1007\/s40257-026-01059-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01029-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:31:39Z","timestamp":1789464699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01029-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01029-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in Table 1, Figure 3 and Supplement file.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-026-01059-6","URL":"https:\/\/doi.org\/10.1007\/s40257-026-01059-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maryanne Senna has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator or a speaker for AbbVie, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Inmagene, LEO Pharma, Merck, Pfizer Inc, Sun Pharmaceutical, and Kintor. She is a scientific advisor for BiologicsMD. Jennifer Soung is a speaker for Celgene, Regeneron\/Sanofi, and Ortho Dermatologics; a speaker and investigator for Amgen, AbbVie, and Pfizer; a speaker, investigator, and advisor for Eli Lilly; an investigator and advisor for LEO Pharma; an investigator, speaker, and consultant for Novartis; an investigator for UCB, Janssen, Kyowa Kirin, KoBioLabs, and Castle Biosciences; an investigator and consultant for Dermavant; a speaker and consultant for Bristol Myers Squibb; and\u00a0a speaker, investigator, and a consultant for Arcutis. Ignasi Figueras has served as an advisory board member, consultant, and\/or investigator for AbbVie, Eli Lilly and Company, LEO Pharma, L\u2019Or\u00e9al, Pfizer, Novartis, Sanofi, Celgene, Amgen, Galderma, and Gebro Pharma, and speaker for AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Sanofi, Novartis, Sobi, Pierre Fabre, La Roche-Posay, Galderma, and Gebro Pharma. Brett King has served on advisory boards, is a consultant, is a clinical trial investigator, and\/or is on a data monitoring committee for AbbVie, AltruBio, Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka\/Visterra, Inc, Pfizer Inc, Q32 Bio, Inc, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, TWi Biotechnology, Inc, Viela Bio, and Ventyx Biosciences, Inc; and has served on speakers bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. Misaki Kinoshita-Ise is a clinical trial investigator for AbbVie, Eli Lilly Japan, Pfizer, and\u00a0Bristol Myers Squibb, and a speaker for Eli Lilly Japan and Pfizer. Sameh Hanna is a clinical trialist with AbbVie, Lilly, Lumenis, and Pfizer, and has received honoraria for speaking\/consulting from AbbVie, Lilly, and Pfizer. Wenyu Wu is a clinical trial investigator and a speaker for AbbVie, Eli Lilly, and Pfizer. Dalia Wajsbrot, Deborah Woodworth, Robert Wolk, Alanna Chaudhry, Alexandre Lejeune, and Helen Tran\u00a0are employees of, and may hold stock or stock options in, Pfizer Inc.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained for the\u00a0individual studies included in the analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants of the individual studies included in this analysis.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See\n                      \n                      for more information.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used for model development is not publicly available. Additional details regarding the model may be provided by the authors upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the concept and design of the study, to data analysis and interpretation, and\u00a0to critical revision of the publication, and all authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}